Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||ASP2453 + Erlotinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ASP2453||KRAS G12C inhibitor 18||ASP2453 is a selective inhibitor of KRAS G12C, which blocks downstream signaling and potentially inhibits growth of tumor cells harboring KRAS G12C (PMID: 34795410).|
|Erlotinib||Tarceva||CP358774||EGFR Inhibitor (Pan) 54 EGFR Inhibitor 1st gen 3||Tarceva (erlotinib) is a first-generation EGFR inhibitor that blocks EGFR signaling, potentially leading to inhibition of tumor growth (PMID: 30069756). Tarceva (erlotinib) is FDA approved for use in patients with non-small cell lung cancer harboring EGFR exon 19 deletions and/or EGFR L858R, and in combination with gemcitabine for patients with locally advanced, unresectable, or metastatic pancreatic cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|